Pfizer Beheer

Beheer criteriumcontroles 3/4

De CEO Pfizer is Albert Bourla, benoemd in Jan2019, heeft een ambtstermijn van 5.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 21.56M, bestaande uit 8.3% salaris en 91.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.006% van de aandelen van het bedrijf, ter waarde ARS 8.59B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.8 jaar en 7.8 jaar.

Belangrijke informatie

Albert Bourla

Algemeen directeur

US$21.6m

Totale compensatie

Percentage CEO-salaris	8.3%
Dienstverband CEO	5.8yrs
Eigendom CEO	0.006%
Management gemiddelde ambtstermijn	5.8yrs
Gemiddelde ambtstermijn bestuur	7.8yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Albert Bourla's beloning veranderd ten opzichte van Pfizer's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 29 2024	n/a	n/a	US$4b
Jun 30 2024	n/a	n/a	-US$3b
Mar 31 2024	n/a	n/a	-US$288m
Dec 31 2023	US$22m	US$2m	US$2b
Oct 01 2023	n/a	n/a	US$10b
Jul 02 2023	n/a	n/a	US$21b
Apr 02 2023	n/a	n/a	US$29b
Dec 31 2022	US$33m	US$2m	US$31b
Oct 02 2022	n/a	n/a	US$30b
Jul 03 2022	n/a	n/a	US$29b
Apr 03 2022	n/a	n/a	US$25b
Dec 31 2021	US$24m	US$2m	US$22b
Oct 03 2021	n/a	n/a	US$19b
Jul 04 2021	n/a	n/a	US$12b
Apr 04 2021	n/a	n/a	US$9b
Dec 31 2020	US$21m	US$2m	US$7b
Sep 27 2020	n/a	n/a	US$212m
Jun 28 2020	n/a	n/a	US$7b
Mar 29 2020	n/a	n/a	US$9b
Dec 31 2019	US$18m	US$2m	US$11b
Sep 29 2019	n/a	n/a	US$16b
Jun 30 2019	n/a	n/a	US$13b
Mar 31 2019	n/a	n/a	US$11b
Dec 31 2018	US$10m	US$1m	US$4b
Sep 30 2018	n/a	n/a	US$24b
Jul 01 2018	n/a	n/a	US$23b
Apr 01 2018	n/a	n/a	US$22b
Dec 31 2017	US$9m	US$1m	US$21b

Compensatie versus markt: De totale vergoeding ($USD 21.56M ) Albert } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de AR markt ($USD 5.73M ).

Compensatie versus inkomsten: De vergoeding van Albert is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Albert Bourla (62 yo)

5.8yrs

Tenure

US$21,562,064

Compensatie

Dr. Albert Bourla, DVM, Ph.D. serves as the Chief Executive Officer of Pfizer Inc. since January 1, 2019 and serves as its Chairman and director of the Board since January 2020 and had been its Executive D...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Albert Bourla	Chairman of the Board & CEO	5.8yrs	US$21.56m	0.0059% ARS 8.6b
David Denton	Chief Financial Officer & Executive VP	2.5yrs	US$5.28m	0.00067% ARS 980.2m
Mikael Dolsten	Chief Scientific Officer and President of Research & Development	5.8yrs	US$8.86m	0.0057% ARS 8.4b
Douglas Lankler	Executive VP & General Counsel	10.9yrs	US$5.48m	0.0026% ARS 3.8b
Jennifer Damico	Senior VP	4.7yrs	geen gegevens	0.00015% ARS 219.5m
Lidia Fonseca	Executive VP and Chief Digital & Technology Officer	5.8yrs	geen gegevens	geen gegevens
Francesca DeMartino	Chief Investor Relations Officer	no data	geen gegevens	geen gegevens
Rady Johnson	Executive VP and Chief Compliance	10.9yrs	geen gegevens	0.0018% ARS 2.7b
Andreas Panayiotou	Global Chief Marketing Officer	2.2yrs	geen gegevens	geen gegevens
Payal Becher	Chief People Experience Officer & Executive VP	4.4yrs	geen gegevens	0.00063% ARS 921.7m
Sally Susman	Executive VP & Chief Corporate Affairs Officer	16.8yrs	geen gegevens	0.0029% ARS 4.2b
Annette Doherty	Head of Worldwide Pharmaceutical Sciences	19.5yrs	geen gegevens	geen gegevens

5.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PFE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Albert Bourla	Chairman of the Board & CEO	4.8yrs	US$21.56m	0.0059% ARS 8.6b
Shantanu Narayen	Lead Independent Director	11.2yrs	US$430.00k	geen gegevens
Ronald Blaylock	Independent Director	7.8yrs	US$380.00k	0.00023% ARS 336.5m
Suzanne Nora Johnson	Independent Director	17.2yrs	US$410.00k	0.00018% ARS 263.3m
James Smith	Independent Director	10.4yrs	US$390.00k	0.000060% ARS 87.8m
Charles Hagel	Member of Emerging Markets Advisory Board	no data	geen gegevens	geen gegevens
Susan Hockfield	Independent Director	4.7yrs	US$363.00k	geen gegevens
Daniel Littman	Independent Director	6.7yrs	US$391.40k	geen gegevens
James Robert Quincey	Independent Director	4.8yrs	US$380.00k	geen gegevens
Scott Gottlieb	Independent Director	5.4yrs	US$417.20k	0.00018% ARS 263.3m
Joseph Echevarria	Independent Director	9.4yrs	US$390.00k	geen gegevens
Helen Hobbs	Independent Director	12.9yrs	US$410.00k	geen gegevens

7.8yrs

Gemiddelde duur

65.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PFE wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.8 jaar).

Pfizer Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Pfizer Inc. Announces Executive Changes

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Recent updates

Pfizer Inc. Announces Executive Changes

Pfizer Reportedly Explore Sale of Hospital Drugs Unit

Pfizer, Inc. and Global Blood Therapeutics, Inc. Sued over Alleged Sickle Cell Drug Side Effects

Pfizer Inc. Revises Earnings Guidance for the Year 2024

Pfizer Inc. Announces Advisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

Pfizer Inc. Announces Election of Mortimer J. Buckley to Its Board of Directors

U.S. FDA Approves Pfizer Inc.’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

Pfizer Inc. Announces Positive Topline Results from the Final Prespecified Overall Survival Analysis of the TALAPRO-2 Study of TALZENNA®

Starboard Value Wants Pfizer to Make Changes to Turn its Performance Around

Pfizer Intends to Sell About 540 Million Ordinary Shares in Haleon

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Pfizer Inc. to Report Q3, 2024 Results on Oct 29, 2024

Pfizer Announces its BRAFTOVI + MEKTOVI Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

Pfizer Appoints Elif Aral as Regional President for Middle East, Russia, and Africa (MERA)

Valneva SE and Pfizer Inc. Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidate

Albertsons Companies, Inc. Offers the Latest Monovalent mRNA COVID Vaccines from Pfizer and Moderna Along with the Annual Flu Vaccine

Pfizer Inc. Launches PfizerForAll

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Pfizer Inc Announces Results of ABRYSVO® for RSV in Immunocompromised Adults

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd